BNP Paribas Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.69M | Sell |
9,813
-309
| -3% | -$57.3K | ﹤0.01% | 1100 |
|
|
2025
Q4 | $2.02M | Buy |
+10,122
| New | +$1.84M | ﹤0.01% | 1062 |
|
|
2025
Q3 | – | Sell |
-1,909
| Closed | -$290K | – | 1915 |
|
|
2025
Q2 | $290K | Buy |
1,909
+413
| +28% | +$55.1K | ﹤0.01% | 830 |
|
|
2025
Q1 | $225K | Sell |
1,496
-3,119
| -68% | -$523K | ﹤0.01% | 851 |
|
|
2024
Q4 | $852K | Sell |
4,615
-137,811
| -97% | -$26.5M | ﹤0.01% | 784 |
|
|
2024
Q3 | $28.1M | Sell |
142,426
-63,588
| -31% | -$13.2M | 0.07% | 254 |
|
|
2024
Q2 | $42.6M | Buy |
206,014
+1,970
| +1% | +$446K | 0.11% | 196 |
|
|
2024
Q1 | $55.3M | Sell |
204,044
-50,772
| -20% | -$12.1M | 0.15% | 162 |
|
|
2023
Q4 | $60.2M | Buy |
254,816
+1,737
| +0.7% | +$342K | 0.17% | 149 |
|
|
2023
Q3 | $49.6M | Buy |
253,079
+52,228
| +26% | +$10.7M | 0.15% | 165 |
|
|
2023
Q2 | $42.2M | Buy |
200,851
+33,172
| +20% | +$6.6M | 0.13% | 181 |
|
|
2023
Q1 | $33.8M | Sell |
167,679
-28,357
| -14% | -$6.43M | 0.12% | 193 |
|
|
2022
Q4 | $42.7M | Buy |
196,036
+22,918
| +13% | +$5M | 0.15% | 165 |
|
|
2022
Q3 | $34.1M | Sell |
173,118
-18,266
| -10% | -$3.94M | 0.13% | 175 |
|
|
2022
Q2 | $41M | Buy |
191,384
+5,461
| +3% | +$1.33M | 0.16% | 157 |
|
|
2022
Q1 | $52.8M | Buy |
185,923
+12,387
| +7% | +$3.82M | 0.18% | 136 |
|
|
2021
Q4 | $65.4M | Buy |
173,536
+13,755
| +9% | +$5.34M | 0.22% | 106 |
|
|
2021
Q3 | $65.9M | Buy |
159,781
+4,416
| +3% | +$1.83M | 0.24% | 94 |
|
|
2021
Q2 | $57.5M | Sell |
155,365
-48,004
| -24% | -$16M | 0.2% | 122 |
|
|
2021
Q1 | $58.9M | Sell |
203,369
-3,069
| -1% | -$853K | 0.24% | 97 |
|
|
2020
Q4 | $51.6M | Buy |
206,438
+5,690
| +3% | +$1.36M | 0.24% | 104 |
|
|
2020
Q3 | $45.5M | Buy |
200,748
+39,002
| +24% | +$8.09M | 0.26% | 100 |
|
|
2020
Q2 | $28.2M | Buy |
161,746
+17,482
| +12% | +$2.79M | 0.19% | 146 |
|
|
2020
Q1 | $18.2M | Buy |
144,264
+16,755
| +13% | +$2.51M | 0.16% | 179 |
|
|
2019
Q4 | $19.5M | Sell |
127,509
-7,911
| -6% | -$1.1M | 0.13% | 210 |
|
|
2019
Q3 | $17.9M | Sell |
135,420
-628
| -0.5% | -$84.2K | 0.14% | 202 |
|
|
2019
Q2 | $19.3M | Sell |
136,048
-18,906
| -12% | -$2.56M | 0.16% | 177 |
|
|
2019
Q1 | $22.5M | Buy |
154,954
+336
| +0.2% | +$44.1K | 0.19% | 146 |
|
|
2018
Q4 | $17.3M | Buy |
154,618
+9,056
| +6% | +$1.13M | 0.16% | 172 |
|
|
2018
Q3 | $19.6M | Sell |
145,562
-8,116
| -5% | -$1M | 0.15% | 191 |
|
|
2018
Q2 | $17.3M | Buy |
153,678
+9,122
| +6% | +$986K | 0.14% | 190 |
|
|
2018
Q1 | $15.4M | Buy |
144,556
+5,775
| +4% | +$622K | 0.13% | 215 |
|
|
2017
Q4 | $15.2M | Sell |
138,781
-5,614
| -4% | -$611K | 0.13% | 223 |
|
|
2017
Q3 | $15.6M | Buy |
144,395
+886
| +0.6% | +$91K | 0.13% | 208 |
|
|
2017
Q2 | $14.5M | Sell |
143,509
-69,098
| -33% | -$6.36M | 0.13% | 209 |
|
|
2017
Q1 | $19.1M | Sell |
212,607
-47,303
| -18% | -$4.02M | 0.18% | 133 |
|
|
2016
Q4 | $19.8M | Buy |
259,910
+54,644
| +27% | +$4.15M | 0.19% | 130 |
|
|
2016
Q3 | $17.1M | Sell |
205,266
-34,195
| -14% | -$2.87M | 0.15% | 181 |
|
|
2016
Q2 | $19.7M | Buy |
239,461
+188,347
| +368% | +$15.5M | 0.17% | 155 |
|
|
2016
Q1 | $3.88M | Buy |
+51,114
| New | +$3.78M | 0.03% | 523 |
|
|
2014
Q1 | – | Sell |
-9,600
| Closed | -$509K | – | 922 |
|
|
2013
Q4 | $509K | Hold |
9,600
| – | – | ﹤0.01% | 768 |
|
|
2013
Q3 | $444K | Sell |
9,600
-263,300
| -96% | -$12.1M | ﹤0.01% | 759 |
|
|
2013
Q2 | $11.2M | Buy |
+272,900
| New | +$11.7M | 0.08% | 287 |
|
Other funds holding CRL
VCM
VPM
BNP Paribas Asset Management's CRL Position: Q1 2026 in Review
BNP Paribas Asset Management reduced its Charles River Laboratories (CRL) stake by 3.1% in Q1 2026, selling an estimated $57.3K and leaving 9,813 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1100.
BNP Paribas Asset Management first reported a position in CRL in Q2 2013 and has held it in 43 quarters since. The position peaked at $65.9M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- BNP Paribas Asset Management held 9,813 shares of Charles River Laboratories worth $1.69M as of Q1 2026.
- BNP Paribas Asset Management sold 309 Charles River Laboratories shares in Q1 2026, an estimated $57.3K.
- Charles River Laboratories made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1100 holding.
- BNP Paribas Asset Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 43 quarters since.
- BNP Paribas Asset Management's Charles River Laboratories position peaked at $65.9M in Q3 2021.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.